Navigation Links
Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
Date:4/23/2012

WASHINGTON, April 23, 2012 /PRNewswire/ --  Covington & Burling represented AstraZeneca in its $1.26 billion acquisition of Ardea Biosciences.  Under the agreement, AstraZeneca will pay $32 per share for all of the outstanding shares of Ardea. 

(Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO )

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. Ardea is a biotechnology company based in San Diego, California, focused on the development of small-molecule therapeutics for the treatment of serious diseases. 

The Covington team was led by Catherine Dargan, with assistance from Stephen Infante and Michael Riella. The team also included John Hurvitz, Emily Leonard, Ashley Nelson, Darien Capron, Brianna Sandoval, Christina Chung, Larry Bartenev and Caitlin Cottingham (life sciences/corporate), Robert Heller and Sarah Burnham (tax), Michael Francese and Katherine Mineka (benefits), Marialuisa Gallozzi and Scott Levitt (insurance), Andrea Reister and Marie Lavalleye (intellectual property), Michael Labson (regulatory), and Deborah Garza, James Dean and Jonathan Herczeg (antitrust). 

Covington & Burling LLP, an international law firm, provides corporate, litigation, and regulatory expertise to enable clients to achieve their goals.  Founded in 1919, the firm has more than 800 lawyers and offices in Beijing, Brussels, London, New York, San Diego, San Francisco, Silicon Valley, and Washington, DC.

Contact

Rebecca Carr


202.662.5110



SOURCE Covington & Burling
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. nanoTox COO Greg King Advises Nanotech Companies to View Safety Concerns as an Opportunity to Gain Consumer Trust
2. KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
3. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
4. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
5. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
6. AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer
7. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
8. Rigel Earns Milestone Payments From AstraZeneca
9. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
10. AstraZeneca Outlines Principles for Product-Related Online Communications
11. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Research and Markets ( ... "Biotechnology for the Non-Biotechnologist" conference to ... ideal for non-Scientists and Scientists needing to understand ... biotechnology. Ideal for Non-Scientists and Scientists ... and potential of biotechnology Why you ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
(Date:7/3/2015)... WIEN , July 3, ... Tiedemiehet voivat hakea verkossa osoitteessa  ... for Open Innovation in Science" ... Ludwig Boltzmann Gesellschaftin (LBG) tekemän, ... tutkimuksen mukaan terveystieteiden kaksi suurinta ...
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at till det ... Science" som hålls i Wien ... undersökning med internationella forskare och vetenskapsmän som ... hälsovetenskapens två största utmaningar bristen på incitament ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... Amnis Corporation and Gene Company, Ltd.,announced today ... Company,will sell and service the Amnis ImageStream(R) system ... Hong Kong, Shanghai,Beijing and Guangzhou now have access ... extremely pleased to have begun what we expect ...
... and Company) (NYSE: BDX ), a global medical technology company,announced ... Bank of America 2008 Healthcare Conference ... Bernstein 24th Annual Strategic Decisions Conference 2008 ... A live webcast of BD,s presentations can be accessed from the ...
... May 7 /PRNewswire-FirstCall/ Varian, Inc. (NasdaqGS:,VARI) announced that ... Glover,as a new director. Glover is the seventh ... appointed for a term expiring at the annual ... is Senior Vice President, Operations and Chief Financial ...
Cached Biology Technology:Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China 2James T. Glover Appointed to Board of Directors of Varian, Inc. 2
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Sharp has selected ... secure authentication for its latest flagship smartphone device, ... than 200 million shipments of its fingerprint ID ... Synaptics, strength, scalability and leadership in the biometrics ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... in behaviour among the population have accelerated the recent decline ... in Science shows how there has been an almost 50 ... researchers attribute to people delaying when they first have sex ... fell most steeply at young ages, with a drop in ...
... one of the oldest healing remedies known to medicine, ... A review article in the most recent issue of ... the data. , Scientists performed 22 trials involving 2,062 ... 16 trials that were performed on experimental animals. Honey ...
... created in this cool movie , ,Scientists ... created polymer nanotubes that are unusually long (about 1 centimeter) ... Described in a new paper in Proceedings of the National ... as channels for tiny volumes of chemicals in nanofluidic reactor ...
Cached Biology News:HIV decline in Zimbabwe linked to behavioural change 2Stable polymer nanotubes may have a biotech future 2
Umbilical cord blood mesenchymal stem cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Biology Products: